The objective of this paper was to identify oral bioavailability enhancing approaches for a
poorly water-soluble research compound during drug discovery stages using minimal amounts …

This article describes the role and responsibilities of the Developability Assessment Group (DAG),
a pharmaceutical Research and Development (R&D) subgroup, which supports drug …

Solubilization of parenteral drugs is a high unmet need in both preclinical and clinical drug
development. Recently, co-amorphous drug formulation has emerged as a new strategy to …

A co-crystal is defined as a single crystalline structure composed of two or more components
with no proton transfer which are solid at room temperature. Our group has come up with …

Utilizing peptides as therapeutic agents is considered an attractive approach for the treatment
of various diseases due to their high binding and selectivity to novel drug targets. However…

This chapter summarizes the significance of suspension in preclinical development. Majority
of the preclinical studies are carried out using suspension. Therefore, it is important to know …

The aim of this work is to highlight the importance of the early characterization of physico-chemical
properties to design an intravenous infusion regimen for a poorly water-soluble …

This chapter will focus on how to overcome biopharmaceutical and technical hurdles of a
given compound during drug discovery and determine a go/no-go development path utilizing …

of the optimal formulation technology is typically not available during discovery and early
development stages due to limitations in both time and material. As a consequence, a number …

In this chapter we discuss oral peptide delivery from a biopharmaceutics perspective to help
understand how peptides and formulations can be designed to induce flux across the …